{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:53Z","timestamp":1790255213776,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N93020D00005"],"award-info":[{"award-number":["75N93020D00005"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["519840568"],"award-info":[{"award-number":["519840568"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2024.080.1"],"award-info":[{"award-number":["2024.080.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["853433"],"award-info":[{"award-number":["853433"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201286","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:52:12Z","timestamp":1782852732000},"page":"201286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner"],"prefix":"10.1016","volume":"34","author":[{"given":"Lorenz","family":"Hanesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Glau\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1079-3633","authenticated-orcid":false,"given":"Jennifer","family":"Altomonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201286_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/eji.1830260323","article-title":"Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells","volume":"26","author":"Heufler","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201286_bib3","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.4049\/jimmunol.181.12.8576","article-title":"IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17","volume":"181","author":"Henry","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib4","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.4049\/jimmunol.154.10.5071","article-title":"Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells","volume":"154","author":"Macatonia","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2013.00082","article-title":"Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells","volume":"4","author":"Hubo","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib7","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.4049\/jimmunol.158.6.2723","article-title":"Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules","volume":"158","author":"Shen","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201286_bib9","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1038\/s41467-021-25307-x","article-title":"CD11b+ lung dendritic cells at different stages of maturation induce Th17 or Th2 differentiation","volume":"12","author":"Izumi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201286_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/smim.2001.0323","article-title":"Dendritic cell subsets and the regulation of Th1\/Th2 responses","volume":"13","author":"Maldonado-L\u00f3pez","year":"2001","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib11","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","article-title":"CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo","volume":"192","author":"den Haan","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201286_bib12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201286_bib13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2026.201286_bib14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1084\/jem.20070176","article-title":"A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo","volume":"204","author":"Soares","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201286_bib15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176913","article-title":"Immunogenic cell death-based oncolytic virus therapy: A sharp sword of tumor immunotherapy","volume":"981","author":"Zhang","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omton.2026.201286_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41417-021-00351-3","article-title":"Cutting both ways: the innate immune response to oncolytic virotherapy","volume":"29","author":"Mealiea","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2026.201286_bib18","article-title":"Heating it up: Oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201286_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01386-18","article-title":"A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma","volume":"92","author":"Abdullahi","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201286_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/mt.2009.231","article-title":"Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma","volume":"18","author":"Altomonte","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201286_bib21","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.3390\/cancers16193405","article-title":"A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model","volume":"16","author":"Glau\u00df","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201286_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.omto.2023.08.001","article-title":"Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy","volume":"30","author":"Marek","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201286_bib23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/cancers13051044","article-title":"Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma","volume":"13","author":"Krabbe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201286_bib24","article-title":"Syncytial death mediated by oncolytic virus rVSV-NDV dynamically activates immunogenic apoptosis and necroptosis in human lung cancer cells","volume":"33","author":"Kortum","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201286_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aal1713","article-title":"Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells","volume":"2","author":"Dai","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004335","article-title":"Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer","volume":"10","author":"van Vloten","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201286_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002569","article-title":"Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201286_bib28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201286_bib29","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41423-021-00726-4","article-title":"Dendritic cell migration in inflammation and immunity","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0092-8674(00)80059-8","article-title":"CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs","volume":"99","author":"F\u00f6rster","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201286_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","article-title":"Inflammatory cytokines as a third signal for T cell activation","volume":"22","author":"Curtsinger","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib32","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1038\/ncomms8458","article-title":"Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints","volume":"6","author":"Mikucki","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201286_bib33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/bcmd.1998.0201","article-title":"Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region","volume":"24","author":"Poltorak","year":"1998","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.omton.2026.201286_bib34","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00018-020-03656-y","article-title":"TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling","volume":"78","author":"Ciesielska","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omton.2026.201286_bib35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00262-014-1600-5","article-title":"New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia","volume":"63","author":"Subklewe","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201286_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1479-5876-5-18","article-title":"Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70","volume":"5","author":"Zobywalski","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201286_bib37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2019.02.056","article-title":"RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade","volume":"41","author":"Heidegger","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omton.2026.201286_bib38","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5'-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201286_bib39","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.omton.2026.201286_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201286_bib41","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201286_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201286_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201286_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy289.002","article-title":"Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB\u2013IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study","volume":"29","author":"Gogas","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2026.201286_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201286_bib46","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201286_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144619","article-title":"Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade","volume":"6","author":"Nair","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201286_bib48","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.3390\/v7122953","article-title":"Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy","volume":"7","author":"Kim","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2026.201286_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.733800","article-title":"Control of Dendritic Cell Function Within the Tumour Microenvironment","volume":"13","author":"Gupta","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175712","article-title":"Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma","volume":"12","author":"Brencicova","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201286_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-9966-31-3","article-title":"Inhibition of dendritic cell migration by transforming growth factor-\u03b21 increases tumor-draining lymph node metastasis","volume":"31","author":"Imai","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201286_bib52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/1042819031000149368","article-title":"Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation","volume":"45","author":"Tough","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omton.2026.201286_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1959140","article-title":"Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants","volume":"10","author":"Pipperger","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201286_bib54","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fimmu.2019.00466","article-title":"TLR7 Controls VSV Replication in CD169+ SCS Macrophages and Associated Viral Neuroinvasion","volume":"10","author":"Solmaz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib55","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1073\/pnas.0400937101","article-title":"Recognition of single-stranded RNA viruses by Toll-like receptor 7","volume":"101","author":"Lund","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201286_bib56","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10070216","article-title":"Fusogenic Viruses in Oncolytic Immunotherapy","volume":"10","author":"Krabbe","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201286_bib58","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-007-0214-1","article-title":"Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference","volume":"85","author":"Chaput","year":"2007","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.omton.2026.201286_bib59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201286_bib60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201286_bib61","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1073\/pnas.071477498","article-title":"Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells","volume":"98","author":"MacAry","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201286_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-065X.1996.tb00920.x","article-title":"CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model","volume":"153","author":"van Gool","year":"1996","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omton.2026.201286_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.2009.00784.x","article-title":"Mechanisms of costimulation","volume":"229","author":"Sharpe","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omton.2026.201286_bib64","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1084\/jem.189.3.451","article-title":"Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization","volume":"189","author":"Gunn","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201286_bib65","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.4049\/jimmunol.1700377","article-title":"A Novel Computational Model Predicts Key Regulators of Chemokine Gradient Formation in Lymph Nodes and Site-Specific Roles for CCL19 and ACKR4","volume":"199","author":"Jafarnejad","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib66","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4049\/jimmunol.176.2.803","article-title":"CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes","volume":"176","author":"Jang","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib67","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fcell.2019.00212","article-title":"CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention","volume":"7","author":"Yan","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2026.201286_bib68","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ni.2085","article-title":"Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration","volume":"12","author":"Braun","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib69","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1084\/jem.166.4.1084","article-title":"Biochemical characterization of a gamma interferon-inducible cytokine (IP-10)","volume":"166","author":"Luster","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201286_bib70","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201286_bib71","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fimmu.2020.01276","article-title":"Antigen Cross-Presentation by Macrophages","volume":"11","author":"Muntjewerff","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201286_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004159","article-title":"Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins","volume":"10","author":"Fessenden","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201286_bib73","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1126\/science.aat5030","article-title":"WDFY4 is required for cross-presentation in response to viral and tumor antigens","volume":"362","author":"Theisen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201286_bib74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00262-004-0602-0","article-title":"Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory","volume":"54","author":"Schirrmacher","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201286_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051103","article-title":"Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients","volume":"18","author":"Schirrmacher","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201286_bib76","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3892\/ol.2014.2588","article-title":"Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report","volume":"8","author":"Schirrmacher","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omton.2026.201286_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7030066","article-title":"Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy","volume":"7","author":"Schirrmacher","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2026.201286_bib78","article-title":"Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine","volume":"4","author":"Dan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2026.201286_bib79","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.22546","article-title":"Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats","volume":"48","author":"Altomonte","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.omton.2026.201286_bib80","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood-2013-12-545772","article-title":"Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow","volume":"124","author":"Mayer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201286_bib81","series-title":"R: A Language and Environment for Statistical","year":"2021"}],"updated-by":[{"DOI":"10.1016\/j.omton.2026.201286","type":"removal","label":"Removal","source":"publisher","updated":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000}}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:38:30Z","timestamp":1790253510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001621"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201286","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201286"}}